Last reviewed · How we verify
DLI of the 20 fraction of the UCBT
DLI of the 20 fraction of the UCBT is a Small molecule drug developed by Banc de Sang i Teixits. It is currently in Phase 1 development.
At a glance
| Generic name | DLI of the 20 fraction of the UCBT |
|---|---|
| Sponsor | Banc de Sang i Teixits |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DLI of the 20 fraction of the UCBT CI brief — competitive landscape report
- DLI of the 20 fraction of the UCBT updates RSS · CI watch RSS
- Banc de Sang i Teixits portfolio CI
Frequently asked questions about DLI of the 20 fraction of the UCBT
What is DLI of the 20 fraction of the UCBT?
DLI of the 20 fraction of the UCBT is a Small molecule drug developed by Banc de Sang i Teixits.
Who makes DLI of the 20 fraction of the UCBT?
DLI of the 20 fraction of the UCBT is developed by Banc de Sang i Teixits (see full Banc de Sang i Teixits pipeline at /company/banc-de-sang-i-teixits).
What development phase is DLI of the 20 fraction of the UCBT in?
DLI of the 20 fraction of the UCBT is in Phase 1.